Gilead Sciences | GILD - Capital Ordinaire





Capital Ordinaire Changement Date
AbbVie USD 1.77B 608K 2026-06
Agios Pharmaceuticals USD 59.6M 264K 2026-06
ALKERMES USD 168.03M 489K 2026-09
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amgen USD 541M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.68M 141K 2026-09
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Glaxosmithkline GBP 2.02B 2.03B 2026-09
Incyte USD 200.98M 1.03M 2026-06
J&J USD 2.41B 1.64M 2026-06
Merck USD 2.47B 1.05M 2026-06
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Pfizer USD 5.7B 1000K 2026-09
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.2B 0 2026-09
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
United Therapeutics USD 42.38M 295K 2026-09
Vertex Pharmaceuticals USD 253.5M 200K 2026-09